ID Biomedical To Decide On 2005 U.S. Flu Vaccine Production By Late January
This article was originally published in The Pink Sheet Daily
Executive Summary
Vancouver-based company will meet with FDA in January to determine whether it will be able to pursue accelerated licensure for Fluviral. The company has reached guaranteed U.S. purchase and distribution agreements with Henry Schein, AmerisourceBergen and McKesson potentially worth $2.5 bil. over 10 years.
You may also be interested in...
Chiron To Meet With U.K. Regulatory Authorities On Fluvirin Suspension
The company does not anticipate the three-month manufacturing suspension will be lifted following the Oct. 6 meeting. Chiron's projected 48 mil. doses of flu vaccine were expected to account for nearly 50% of the U.S. supply.
GSK To Gain Fluviral Vaccine Through Acquisition Of ID Biomedical
GlaxoSmithKline plans to acquire ID Biomedical for $1.4 bil., a deal that could provide GSK with a second flu vaccine in the U.S. for the 2006/2007 flu season.
GSK To Gain Fluviral Vaccine Through Acquisition Of ID Biomedical
GlaxoSmithKline plans to acquire ID Biomedical for $1.4 bil., a deal that could provide GSK with a second flu vaccine in the U.S. for the 2006/2007 flu season.